Clinical Trial Update: A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

An ongoing Phase 1b/2 clinical trial is evaluating combinations with trastuzumab deruxtecan (T-DXd) for HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING